2015 ACC Medical Meeting Reporter: Best Practices in Lipid Management for Patients with Dyslipidemia

Pre-Activity Questions

1. Please use the scale below to rate your level of confidence as it relates to your knowledge/skill level PRIOR to participating in this activity. *

1=NOT at all confident, 2=Somewhat confident, 3=Confident, 4=Very confident, 5=EXTREMELY confident, N/A=Not within the scope of my practice

	1	2	3	4	5	N/A
Your ability to develop individualized treatment plans for patients with dyslipidemia	Your ability to develop individualized treatment plans for patients with dyslipidemia - 1	Your ability to develop individualized treatment plans for patients with dyslipidemia - 2	Your ability to develop individualized treatment plans for patients with dyslipidemia - 3	Your ability to develop individualized treatment plans for patients with dyslipidemia - 4	Your ability to develop individualized treatment plans for patients with dyslipidemia - 5	Your ability to develop individualized treatment plans for patients with dyslipidemia - N/A
Your ability to apply current ACC/AHA guidelines to your everyday practice	Your ability to apply current ACC/AHA guidelines to your everyday practice - 1	Your ability to apply current ACC/AHA guidelines to your everyday practice - 2	Your ability to apply current ACC/AHA guidelines to your everyday practice - 3	Your ability to apply current ACC/AHA guidelines to your everyday practice - 4	Your ability to apply current ACC/AHA guidelines to your everyday practice - 5	Your ability to apply current ACC/AHA guidelines to your everyday practice - N/A

2. Many of the PCSK9 inhibitors are administered to patients via injection. Which of the following therapeutic options is a first-in-class orally available LDL-C lowering molecule? *

Bococizumab

ETC-1002

Evolocumab

Alirocumab

3. One of the many side effects of statin therapy is new-onset diabetes by increasing FSG levels. According to a study presented at ACC 2015, which of the following agents has proved to not further increase FSG levels while administered in combination with statin therapy? *

Ezetimibe

Alirocumab

Statin therapy alone

Evolocumab

4. A study was conducted to evaluate the clinical equivalence of evolocumab given in different dosing regimens. According to this study, which of the following dosing regimens was show to be most effective for in lowering LDL-C levels in participants? *

Evolocumab 140mg Q2W

Evolocumab 420mg QM

Both dosing regimens had similar results in lowering LDL-C levels

Neither dosing regimen effectively lowered LDL-C levels

5. An efficacy and safety analysis of pooled data from 14 trials on alirocumab was presented at ACC 2015 and the results demonstrated no major increase in adverse events in patients with a pharmacologically-induced LDL-C less than: *

50 mg/dL

25 mg/dL

15 mg/dL

B & C

6. How often do you currently use each of the following clinical practice strategies for your patients with dyslipidemia? *

(1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me)

	1	2	3	4	5	N/A
Utilize current recommendations and guidelines when managing patients with dyslipidemia	Utilize current recommendations and guidelines when managing patients with dyslipidemia - 1	Utilize current recommendations and guidelines when managing patients with dyslipidemia - 2	Utilize current recommendations and guidelines when managing patients with dyslipidemia - 3	Utilize current recommendations and guidelines when managing patients with dyslipidemia - 4	Utilize current recommendations and guidelines when managing patients with dyslipidemia - 5	Utilize current recommendations and guidelines when managing patients with dyslipidemia - N/A
Consider the application of PCSK9 therapeutics for patients with statin intolerance	Consider the application of PCSK9 therapeutics for patients with statin intolerance - 1	Consider the application of PCSK9 therapeutics for patients with statin intolerance - 2	Consider the application of PCSK9 therapeutics for patients with statin intolerance - 3	Consider the application of PCSK9 therapeutics for patients with statin intolerance - 4	Consider the application of PCSK9 therapeutics for patients with statin intolerance - 5	Consider the application of PCSK9 therapeutics for patients with statin intolerance - N/A
Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - 1	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - 2	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - 3	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - 4	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - 5	Apply knowledge from clinical trial data to develop individualized treatment plans to maximize patients at LDL-C goals - N/A

Leave this field blank

Elsevier CME

2015 ACC Medical Meeting Reporter: Best Practices in Lipid Management for Patients with Dyslipidemia

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Course navigation

You are here

2015 ACC Medical Meeting Reporter: Best Practices in Lipid Management for Patients with Dyslipidemia

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Course navigation